Quantcast

Latest gene delivery Stories

2014-05-05 08:28:53

TARRYTOWN, N.Y. and MENLO PARK, Calif., May 5, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Avalanche Biotechnologies, Inc., today announced the formation of a broad collaboration to discover, develop and commercialize novel gene therapy products for the treatment of ophthalmologic diseases. The collaboration covers novel gene therapy vectors and proprietary molecules, discovered jointly by Avalanche and Regeneron, and developed using the Avalanche Ocular...

2014-04-24 12:29:16

ALBANY, New York, April 24, 2014 /PRNewswire/ -- According to a new market report published by Transparency Market Research "Transfection Technology Market (Reagent-based method, Instrument-based method and Virus-based method) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" the global transfection technology market was valued at USD 386.4 million in 2012 and is estimated to reach a market worth of USD 768.2 million in 2019growing at a CAGR of...

2014-04-08 08:32:20

DUBLIN, April 8, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/492nrm/gene_therapy) has announced the addition of a new report "Gene Therapy - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/492nrm/gene_therapy ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Gene therapy can be broadly defined as the transfer of defined genetic material to specific target...

2014-04-01 23:23:22

Dr. Beverly Davidson Researches Novel Treatments for Neurological Diseases Philadelphia, PA (PRWEB) April 01, 2014 Beverly L. Davidson, Ph.D., a nationally prominent expert in gene therapy, is joining The Children’s Hospital of Philadelphia (CHOP) today. Dr. Davidson, who investigates gene therapy for neurodegenerative diseases, arrives from the Center for Gene Therapy at the University of Iowa. She served as associate director at that Center, as well as director of the Gene Therapy...

2014-03-25 00:23:24

PHILADELPHIA, March 25, 2014 /PRNewswire/ -- Spark Therapeutics and Genable Technologies announced today that they have entered into a collaboration agreement for Genable's lead therapeutic to treat rhodopsin-linked autosomal dominant retinitis pigmentosa (RHO adRP), GT038. Under the terms of the collaboration, Genable will license certain adeno-associated virus (AAV) vector manufacturing patents from Spark. The parties have entered into a broad agreement in which Spark will be the...

2014-03-19 23:00:54

ReportsnReports.com adds “Cancer Gene Therapy Market Analysis” report to its research database. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Dallas, TX (PRWEB) March 20, 2014 The gene therapy market has undergone a series of transformation from the initial days of research to the current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the...

2014-03-11 04:21:27

BARCELONA, Spain, March 11, 2014 /PRNewswire/ -- - This gene therapy program is being developed in a public-private partnership between ESTEVE and the research team of Dr. Fatima Bosch at the Center for Biotechnology and Gene Therapy of the Universitat Autonoma de Barcelona (UAB) - ESTEVE announce the signing of agreements with REGENX and GENETHON which will allow it to initiate its phase I/II clinical trial in 2015 -...

2014-02-11 08:32:36

Company continues to expand its board and leadership team as it moves toward completion of its Phase 3 gene therapy program and advancement of the industry's deepest pipeline of gene-based medicines PHILADELPHIA, Feb. 11, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage company developing gene-based medicines for a wide range of debilitating diseases, announced today the appointment of Elliott Sigal, M.D., Ph.D., former director, executive vice president and chief scientific officer of...

Eye Gene Therapy
2014-01-16 09:44:41

Brett Smith for redOrbit.com - Your Universe Online A newly developed genetic therapy for treating a type of inherited blindness called choroideremia is showing some promise and allowing patients to see incrementally more than they had before the treatment, according to a new report in The Lancet. Six patients in the study had one eye treated with the gene therapy in operations at the Oxford Eye Hospital in the United Kingdom. After six months, the treated eye showed improved vision in...

2014-01-14 12:26:51

Spark CEO provides corporate updates at the J.P. Morgan Conference SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Spark Therapeutics, a late-stage gene therapy company, has reached its patient recruitment goal for its most advanced clinical program, a Phase 3 study for inherited retinal dystrophies caused by mutations in the RPE65 gene. Spark's CEO, Jeffrey D. Marrazzo, is presenting this and other corporate updates today, at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco....


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.